Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/23/2026, 12:00:00 AM
Initiated a Phase 1 clinical trial for LX9851 on March 23, 2026, a new oral, non-incretin obesity drug candidate licensed from Lexicon Pharmaceuticals.
Korean Translation
2026년 3월 23일 렉시콘 파마슈티컬스로부터 기술 도입한 새로운 경구용, 비인크레틴 계열 비만 치료제 후보물질 LX9851의 1상 임상시험을 개시함.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Novartis AG (NVS) · Earnings Release
First quarter 2026 results scheduled for 2026-04-28; high impact expected as a major financial update.
4/28/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Other
The FDA has set a PDUFA target action date of April 28, 2026, for its review of the New Drug Application for doravirine/islatravir, an investigational HIV treatment. Approval typically impacts price by 5-10%, scheduled.
4/28/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
Quarterly dividend with an ex-dividend date of April 15, 2026, is scheduled.
4/15/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Other
Quarterly dividend of $1.25 per share, announced on March 11, 2026, with an ex-dividend date of March 27, 2026. This represented a 3.1% increase from the prior dividend.
3/27/2026, 12:00:00 AM